239 related articles for article (PubMed ID: 22431062)
1. The pathological roles of BART miRNAs in nasopharyngeal carcinoma.
Lo AK; Dawson CW; Jin DY; Lo KW
J Pathol; 2012 Aug; 227(4):392-403. PubMed ID: 22431062
[TBL] [Abstract][Full Text] [Related]
2. NF-κB Signaling Regulates Expression of Epstein-Barr Virus BART MicroRNAs and Long Noncoding RNAs in Nasopharyngeal Carcinoma.
Verhoeven RJ; Tong S; Zhang G; Zong J; Chen Y; Jin DY; Chen MR; Pan J; Chen H
J Virol; 2016 Jul; 90(14):6475-88. PubMed ID: 27147748
[TBL] [Abstract][Full Text] [Related]
3. BART miRNAs: an unimaginable force in the development of nasopharyngeal carcinoma.
Wang Y; Guo Z; Shu Y; Zhou H; Wang H; Zhang W
Eur J Cancer Prev; 2017 Mar; 26(2):144-150. PubMed ID: 26909566
[TBL] [Abstract][Full Text] [Related]
4. Integrated analysis of the differential cellular and EBV miRNA expression profiles in microdissected nasopharyngeal carcinoma and non-cancerous nasopharyngeal tissues.
Wan XX; Yi H; Qu JQ; He QY; Xiao ZQ
Oncol Rep; 2015 Nov; 34(5):2585-601. PubMed ID: 26330189
[TBL] [Abstract][Full Text] [Related]
5. Clustered microRNAs of the Epstein-Barr virus cooperatively downregulate an epithelial cell-specific metastasis suppressor.
Kanda T; Miyata M; Kano M; Kondo S; Yoshizaki T; Iizasa H
J Virol; 2015 Mar; 89(5):2684-97. PubMed ID: 25520514
[TBL] [Abstract][Full Text] [Related]
6. EBV-encoded miRNAs target ATM-mediated response in nasopharyngeal carcinoma.
Lung RW; Hau PM; Yu KH; Yip KY; Tong JH; Chak WP; Chan AW; Lam KH; Lo AK; Tin EK; Chau SL; Pang JC; Kwan JS; Busson P; Young LS; Yap LF; Tsao SW; To KF; Lo KW
J Pathol; 2018 Apr; 244(4):394-407. PubMed ID: 29230817
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr Virus MicroRNA miR-BART5-3p Inhibits p53 Expression.
Zheng X; Wang J; Wei L; Peng Q; Gao Y; Fu Y; Lu Y; Qin Z; Zhang X; Lu J; Ou C; Li Z; Zhang X; Liu P; Xiong W; Li G; Yan Q; Ma J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30209170
[TBL] [Abstract][Full Text] [Related]
8. Role of Viral and Host microRNAs in Immune Regulation of Epstein-Barr Virus-Associated Diseases.
Iizasa H; Kim H; Kartika AV; Kanehiro Y; Yoshiyama H
Front Immunol; 2020; 11():367. PubMed ID: 32194570
[TBL] [Abstract][Full Text] [Related]
9. Regulation network and expression profiles of Epstein-Barr virus-encoded microRNAs and their potential target host genes in nasopharyngeal carcinomas.
Zeng Z; Huang H; Huang L; Sun M; Yan Q; Song Y; Wei F; Bo H; Gong Z; Zeng Y; Li Q; Zhang W; Li X; Xiang B; Li X; Li Y; Xiong W; Li G
Sci China Life Sci; 2014 Mar; 57(3):315-326. PubMed ID: 24532457
[TBL] [Abstract][Full Text] [Related]
10. BART-D2 subtype of EBV encoded BART miRNA cluster 1 region is strongly associated with endemic nasopharyngeal carcinoma.
Wang Q; He H; Ji X; Liu Y; Li H; Wang Y
J Med Virol; 2023 Mar; 95(3):e28667. PubMed ID: 36912378
[TBL] [Abstract][Full Text] [Related]
11. A single nucleotide polymorphism in the BART promoter region of Epstein-Barr virus isolated from nasopharyngeal cancer cells.
Kim H; Burassakarn A; Kang Y; Iizasa H; Yoshiyama H
Biochem Biophys Res Commun; 2019 Dec; 520(2):373-378. PubMed ID: 31606205
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Epstein-Barr virus miRNAome in nasopharyngeal carcinoma by deep sequencing.
Chen SJ; Chen GH; Chen YH; Liu CY; Chang KP; Chang YS; Chen HC
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20862214
[TBL] [Abstract][Full Text] [Related]
13. Detection of Epstein-Barr virus (EBV)-encoded microRNAs in plasma of patients with nasopharyngeal carcinoma.
Gao W; Wong TS; Lv KX; Zhang MJ; Tsang RK; Chan JY
Head Neck; 2019 Mar; 41(3):780-792. PubMed ID: 30548946
[TBL] [Abstract][Full Text] [Related]
14. Vesicle-bound EBV-BART13-3p miRNA in circulation distinguishes nasopharyngeal from other head and neck cancer and asymptomatic EBV-infections.
Ramayanti O; Verkuijlen SAWM; Novianti P; Scheepbouwer C; Misovic B; Koppers-Lalic D; van Weering J; Beckers L; Adham M; Martorelli D; Middeldorp JM; Pegtel DM
Int J Cancer; 2019 May; 144(10):2555-2566. PubMed ID: 30411781
[TBL] [Abstract][Full Text] [Related]
15. Circulating Epstein-Barr virus microRNAs miR-BART7 and miR-BART13 as biomarkers for nasopharyngeal carcinoma diagnosis and treatment.
Zhang G; Zong J; Lin S; Verhoeven RJ; Tong S; Chen Y; Ji M; Cheng W; Tsao SW; Lung M; Pan J; Chen H
Int J Cancer; 2015 Mar; 136(5):E301-12. PubMed ID: 25213622
[TBL] [Abstract][Full Text] [Related]
16. MicroRNAs serving as potential biomarkers and therapeutic targets in nasopharyngeal carcinoma: A critical review.
Lee KT; Tan JK; Lam AK; Gan SY
Crit Rev Oncol Hematol; 2016 Jul; 103():1-9. PubMed ID: 27179594
[TBL] [Abstract][Full Text] [Related]
17. Nasopharyngeal Carcinoma: An Evolving Role for the Epstein-Barr Virus.
Raab-Traub N
Curr Top Microbiol Immunol; 2015; 390(Pt 1):339-63. PubMed ID: 26424653
[TBL] [Abstract][Full Text] [Related]
18. Pathogenic role of Epstein-Barr virus latent membrane protein-1 in the development of nasopharyngeal carcinoma.
Yoshizaki T; Kondo S; Wakisaka N; Murono S; Endo K; Sugimoto H; Nakanishi S; Tsuji A; Ito M
Cancer Lett; 2013 Aug; 337(1):1-7. PubMed ID: 23689138
[TBL] [Abstract][Full Text] [Related]
19. The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.
Tsang CM; Tsao SW
Virol Sin; 2015 Apr; 30(2):107-21. PubMed ID: 25910483
[TBL] [Abstract][Full Text] [Related]
20. Extra-cellular release and blood diffusion of BART viral micro-RNAs produced by EBV-infected nasopharyngeal carcinoma cells.
Gourzones C; Gelin A; Bombik I; Klibi J; Vérillaud B; Guigay J; Lang P; Témam S; Schneider V; Amiel C; Baconnais S; Jimenez AS; Busson P
Virol J; 2010 Oct; 7():271. PubMed ID: 20950422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
